Two distinct inhibitors of the HCV protease have been approved for the treatment of patients infected with HCV genotype-1. These drugs are highly efficient in suppressing HCV replication; however, their use is limited by the emergence of viral mutants resistant to them after a very short time of treatment. By analysing blood samples, it was shown that viral strains resistant to protease inhibitors (PIs) may exist prior to treatment. The aim of this study was to investigate the presence of viral variants resistant to PIs in isolates from liver and blood of HCV patients naive to any antiviral therapy.
Methods
Liver and blood HCV genotype-1b isolates from 10 patients with chronic hepatitis were analysed by cloning and sequencing procedures.
Results
The analyses of 10–15 clones from liver isolates of each patient showed that 7/10 cases had single or multiple mutations potentially conferring resistance to PIs. However, the analysis of the corresponding blood samples excluded the presence of these mutations in all cases but one, which had the Q80R mutation in all clones from both liver and plasma samples. No PI-resistant variants were detected in isolates from either liver or plasma samples of three patients.
Conclusions
Naturally occurring HCV variants resistant to PIs are commonly present at the intrahepatic level and this clearly explains their usual, very early emergence under treatment; however, the identification of these variants as circulating viral populations is not unusual in untreated patients.
References
1.
McHutchisonJ.G., LawitzE.J., ShiffmanM.L.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med2009; 361: 580–593.
2.
VerbinnenT., VanM.H., VandenbrouckeI.Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol2010; 84: 11124–11133.
3.
QiuP., SanforenzoV., CurryS.Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res2009; 37: e74.
4.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med2009; 360: 1839–1850.
5.
KiefferT.L., SarrazinC., MillerJ.S.Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology2007; 46: 631–639.
6.
KwoP.Y., LawitzE.J., McConeJ.Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet2010; 376: 705–716.
7.
LawitzE., Rodriguez-TorresM., MuirA.J.Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol2008; 49: 163–169.
8.
McHutchisonJ.G., EversonG.T., GordonS.C.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med2009; 360: 1827–1838.
9.
ThompsonA.J., McHutchisonJ.G.Review article: investigational agents for chronic hepatitis C. Aliment Pharmacol Ther2009; 29: 689–705.
10.
GhanyM.G., NelsonD.R., StraderD.B.An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology2011; 54: 1433–1444.
11.
BartelsD.J., ZhouY., ZhangE.Z.Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis2008; 198: 800–807.
12.
GaudieriS., RauchA., PfafferottK.Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology2009; 49: 1069–1082.
13.
HalfonP., LocarniniS.Hepatitis C virus resistance to protease inhibitors. J Hepatol2011; 55: 192–206.
14.
RongL., DahariH., RibeiroR.M.Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med2010; 2: 30–32.
15.
SarrazinC., KiefferT.L., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology2007; 132: 1767–1777.
16.
SarrazinC., ZeuzemS.Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology2010; 138: 447–462.
17.
BartenschlagerR., LohmannV.Replication of hepatitis C virus. J Gen Virol2000; 81: 1631–1648.
18.
ThompsonA.J., McHutchisonJ.G.Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat2009; 16: 377–387.
19.
KuntzenT., TimmJ., BericalA.Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology2008; 48: 1769–1778.
20.
CuberoM., EstebanJ.I., OteroT.Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology2008; 370: 237–245.
